Literature DB >> 465517

Activation of lipoprotein lipase by native and acylated peptides of apolipoprotein C-II.

T A Musliner, P N Herbert, E C Church.   

Abstract

Apolipoprotein C-II, a protein found associated with all major classes of plasma lipoproteins, is a potent activator of the enzyme lipoprotein lipase. We have prepared the maleyl, citraconyl and succinyl derivatives of apolipoprotein C-II, and compared the capacities of the intact and tryptically cleaved proteins to activate lipoprotein lipase. The NH2-terminal 50 residue peptide proved virtually inactive, even after removal of the masking groups from the citraconyl derivative. The COOH-terminal 29 residue peptides of maleyl and citraconyl apolipoprotein C-II were more active than the corresponding succinylated peptide. After deacylation of the citraconyl derivative, the COOH-terminal peptide had maximal activity as great as apolipoprotein C-II, although the profile of activation remained dissimilar at low activator concentrations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465517     DOI: 10.1016/0005-2760(79)90224-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

3.  Purification, cloning and nucleotide sequence determination of cynomolgus monkey apolipoprotein C-II: comparison to the human sequence.

Authors:  B E Whitted; C K Castle; H G Polites; G W Melchior; K R Marotti
Journal:  Mol Cell Biochem       Date:  1989-10-05       Impact factor: 3.396

4.  [Apolipoproteinopathies].

Authors:  G Assmann
Journal:  Klin Wochenschr       Date:  1983-02-15

5.  Apolipoprotein H is not affected by in vitro glycosylation.

Authors:  R Gambino; G Ruiu; G Pagano; M Cassader
Journal:  J Protein Chem       Date:  1999-02

6.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  The effects of chemically modifying serum apolipoproteins on their ability to activate lipoprotein lipase.

Authors:  P F Dodds; A Lopez-Johnston; V A Welch; M I Gurr
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

Review 8.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

9.  Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia.

Authors:  Tian Zhang; Jiawen Yang; Vijaya P Vaikari; John S Beckford; Sharon Wu; Mojtaba Akhtari; Houda Alachkar
Journal:  Blood Cancer Discov       Date:  2020-09

Review 10.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.

Authors:  Anna Wolska; Mart Reimund; Denis O Sviridov; Marcelo J Amar; Alan T Remaley
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.